肝动脉化疗联合艾迪注射液治疗肝癌

[目的]观察化疗联合艾迪注射液肝动脉灌注治疗肝癌的临床效果。[方法]56例原发弥漫性肝癌及98例转移性肝癌随机分为A、B、C三组。其中,A组51例周围静脉化疗,B组51例肝动脉化疗,C组52例化疗联合艾迪注射液肝动脉灌注。治疗4个周期后评价疗效。[结果]A、B、C三组近期有效率分别为31.4%、78.4%、86.5%。1、2、3年生存率,A组分别为50.9%、35.3%、17.6%,B组分别为76.5%、45.1%、21.6%,C组分别为86.5%、65.4%、36.5%。三组比较有明显差异(P<0.05)。治疗后机体免疫功能,与治疗前比较,A、B组下降,C组增高。治疗后A、B组与C组比较,差别明显(P<0.05)。[结论]化疗联合艾迪注射液肝动脉灌注能够增强机体免疫功能,提高晚期肝癌的治疗效果。

Transhepatoarterial Chemotherapy Combined with Aidi Injection for Treatment of Liver Cancer

To investigate the effect of systematic chemotherapy combined with Aidi injection transhepatic arterial infusion in treatment for liver cancer.Fifty-six cases with primary diffuse hepatocarcinoma and98cases with metastasis were randomly divided into three groups:group A,systematic chemotherapy;group B,transhepatoarterial chemotherapy(TAC);group C,TAC and Aidi injection.The effects was evaluated after4courses.The re-sponse rate of group A,B,C was31.4%,78.4%,and86.5%respectively.The1-,2-,3-year survival rates were50.9%,35.3%,17.6%,and76.5%,45.1%,21.6%in group B,and86.5%,65.4%,36.5%in group C respectively.There was obviously different among the three groups(P<0.05).The im-munity decreased in group A,B and increased in group C after treatment,compared with pre-treatment.There was obviously different between A,B groups and group C(P<0.05).[Conclu-sion]The combined therapy is an effective way in treatment of advanced liver cancer.It can en-hance immunity,and increase the therapentic effect.